Bispecific Antibodies
**Note:** The following describes an area of investigational scientific research. BH Onco's cellular products are investigational, have not been approved by the U.S. FDA, and are not offered as a treatment for any disease.
Bispecific Antibodies (BAs) are a specialized form of immunotherapy designed to simultaneously bind to two different targets, enhancing the immune system's ability to attack cancer. One binding site of the bispecific antibody is engineered to attach to a specific antigen on the surface of cancer cells, while the other site binds to immune cells, often T-cells. This dual-targeting mechanism brings the immune cells directly into contact with the cancer cells, facilitating a more precise and potent immune response. By effectively bridging the gap between cancer cells and immune cells, BAs help to focus the immune attack on the tumor, offering a promising strategy for treating various types of cancer, particularly those that have been resistant to other forms of therapy.
Date:
November 29, 2022
Category:
